Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, mesothelin, fibroblast activation protein, epidermal growth factor receptor, carcinoembryonic antigen, disialoganglioside‑2 and human epidermal growth factor 2 are among the main targets of CART‑cell therapy in the case of other types of solid tumors.
|
30542701 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
HER3 is a member of the epidermal growth factor family and was predominantly described as a negative prognostic factor in various solid tumors as well as in ovarian cancer.
|
27913862 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor invasion through a basement membrane is one of the earliest steps in metastasis, and growth factors, such as Epidermal Growth Factor (EGF) and Hepatocyte Growth Factor (HGF), stimulate this process in a majority of solid tumors.
|
28978320 |
2017 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, epidermal growth factor (EGF) signaling pathway modulates the expression of claudins in a number of solid tumors.
|
28160565 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA.
|
22296186 |
2012 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of the EGF receptor (EGFR) is a characteristic finding in a considerable number of solid tumors and often signalizes poor prognosis.
|
18519753 |
2008 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2 (Tie2) has been considered as a rational target for gene therapy in solid tumors.
|
18330476 |
2008 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In searching for EGF target genes, we have identified ERG1.2, the mouse homolog of the solid tumor-associated gene STAG1.
|
14639658 |
2003 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These results demonstrate the potent anti-tumor activity of ABX-EGF and its therapeutic potential for the treatment of multiple human solid tumors that overexpress EGFr.
|
11255078 |
2001 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Trastuzumab (Herceptin) is the first monoclonal antibody to be approved for the treatment of a solid tumour and is directed against the c-erb-B2 receptor. c-erb-B2 is a member of the epidermal growth factor family and approximately 25% of breast cancers express such receptors, which appear to confer a poorer prognosis and may be an indicator of resistance to cytotoxic chemotherapy.
|
11824879 |
2001 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The co-occurrence of Her-2/neu overexpression and EGF receptor overexpression in the same aneuploid cells defines an adeno/squamous genetic evolutionary sequence that is common to ductal breast cancers, non-small cell lung cancers, and other solid tumors.
|
9298807 |
1997 |